roxadustat
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia
Conditions
ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia
Trial Timeline
Jun 2, 2016 → Dec 12, 2017
NCT ID
NCT02780141About roxadustat
roxadustat is a phase 3 stage product being developed by Astellas Pharma for ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02780141. Target conditions include ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05970172 | Phase 3 | Recruiting |
| NCT04408820 | Pre-clinical | Completed |
| NCT04076943 | Phase 2 | Completed |
| NCT03960489 | Phase 1 | Completed |
| NCT02964936 | Phase 3 | Completed |
| NCT02965040 | Phase 1 | Completed |
| NCT02780726 | Phase 3 | Completed |
| NCT02780141 | Phase 3 | Completed |
| NCT02779764 | Phase 3 | Completed |
| NCT01630889 | Phase 2 | Completed |
| NCT01244763 | Phase 2 | Completed |
| NCT01083888 | Phase 1 | Completed |